Transform non-human antibodies into human-like therapeutics with AI-guided framework engineering. Our platform reduces immunogenicity while preserving antigen-binding affinity and developability for clinical advancement.
Antibodies derived from non-human sources, such as murine or camelid origins, carry immunogenic sequences that can trigger adverse immune responses in patients. Antibody humanization redesigns the framework regions of an antibody to resemble human immunoglobulin sequences while retaining the critical complementarity-determining regions (CDRs) responsible for antigen binding.
Our AI-powered humanization platform leverages deep learning models trained on massive antibody repertoires to predict optimal framework mutations. This approach produces humanized antibodies with superior humanness scores, maintained binding affinity, and improved developability profiles compared to conventional CDR grafting alone.
"AI-guided humanization enables systematic framework optimization at scale, balancing immunogenicity reduction with structural and functional integrity."
End-to-end AI-driven humanization covering sequence analysis, framework engineering, and experimental validation.
We humanize antibodies from murine, rat, rabbit, camelid (VHH/nanobodies), and other non-human origins into fully human or humanized frameworks.
Deep learning models trained on billions of antibody sequences predict optimal framework mutations that maximize humanness while preserving structure.
Intelligent identification of critical framework residues requiring back-mutations to maintain CDR conformation and antigen-binding geometry.
Integrated evaluation of aggregation propensity, viscosity, stability, and expressibility to ensure clinical-grade developability.
Support for full-length IgG, Fab fragments, scFv, VHH (nanobodies), and bispecific antibody formats across the humanization pipeline.
Multi-round design cycles that progressively optimize humanness, binding affinity, and developability based on experimental feedback.
High-yield expression of humanized antibodies in CHO or HEK293 cells with full QC characterization, ready for downstream development.
Detailed documentation including sequence alignment, humanness scores, mutation rationale, and binding characterization reports.
A streamlined pipeline combining AI-driven in silico design with rigorous experimental validation.
Our humanization platform serves diverse therapeutic programs across oncology, immunology, infectious disease, and beyond.
Humanized monoclonal antibodies and bispecific antibodies targeting tumor antigens for cancer immunotherapy applications.
Low-immunogenicity antibodies against autoimmune disease targets including IL-17, TNF-alpha, and IL-6 pathways.
Humanized neutralizing antibodies for viral and bacterial pathogens, enabling rapid response therapeutic development.
Engineered bispecific formats with humanized arms enabling dual-target therapeutic strategies.
Conversion of camelid-derived VHH nanobodies into humanized scaffolds while retaining their distinctive paratope architecture.
Humanized antibodies for in vitro diagnostic (IVD) reagent development with reduced background and improved specificity.
Peer-reviewed publications supporting AI-driven approaches to therapeutic antibody humanization.
Common questions about our antibody humanization service.
Partner with our team to transform your non-human antibody into a clinical-ready humanized therapeutic with optimized humanness, affinity, and developability.
Start Your ProjectTell us about your project and we'll get back within 24 hours.
